Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
Akcea Therapeutics and Ionis Pharmaceuticals each made handy gains on Wednesday after the firms reported midstage results for their cardiovascular disease study.
Medicines Co shares shot up on Monday after it was reported that Novartis will be acquiring the firm. The transaction was unanimously approved by the boards of directors of both companies.
Medicines shares shot up on Tuesday after it was reported that Novartis might be eyeing this company as its newest acquisition.
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...
Ionis Pharmaceuticals shares were relatively flat on Wednesday after the company announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases.
Akcea Therapeutics shares pulled back on Monday after the company announced a big change to its board of directors.
Akcea and Ionis Pharmaceuticals shares made a solid gain on Monday after the companies announced positive top-line data for a midstage trial in patients with established cardiovascular disease and...
Akcea and Ionis were each crushed on Tuesday after the firms announced that they received a Complete Response Letter from the FDA.
Akcea Therapeutics shares saw a nice bump on Wednesday after the company announced in conjunction with Ionis Pharmaceuticals that they had received a marketing authorization approval from the...
Ionis Pharmaceuticals shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen.
Akcea Therapeutics expects to price more than 9 million shares in the range of $12 to $14 apiece in an initial public offering valued up to almost $155 million.
Ionis Pharmaceuticals saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment of familial amyloid polyneuropathy.
Akcea Therapeutics has amended its filing with the SEC for its initial public offering.